spacer
home > ebr > summer 2019 > closer to the cure
PUBLICATIONS
European Biopharmaceutical Review

Closer to the Cure

Cancer has always been with us. For most of history, it was entirely untreatable; now, two out of three Americans with invasive cancer survive for at least five years. Overall cancer survival rates in the UK have doubled over the past 40 years; now, most people diagnosed with cancer live for at least 10 more years. Though a lot of progress has been made, it is uneven, and the next set of breakthroughs will require accepting a high risk of failure. We will need to look beyond incremental change towards potential cures.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Christian Rommel is Roche’s Global Head of Pharma Research and Early Development (pRED) Oncology. Before that, he led the pRED Oncology Discovery group from 2014 to 2018. Previous to joining Roche, he held the positions of Vice President of External Research and Development and Vice President of Research Oncology at Amgen. Christian served as Chief Scientific Officer at a private biotechnology company (Intellikine) from its inception to acquisition by Takeda in 2011. Previously, Christian was Head of Target Research at Merck Serono from 2000 to 2007. Over the course of his career, Christian authored more than 70 publications and was an inventor or co-inventor of 18 patents. Christian received his PhD in molecular oncology/signal transduction from the Max Planck Institute in Berlin, Germany, and the Institute of Medical Virology at the University of Zurich, Switzerland.
spacer
Christian Rommel
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

High Throughput Analytics Herald a Paradigm Shift in the Development of Biopharmaceuticals

Heilbronn/Dortmund August 2019: Biopharmaceuticals have revolutionized therapies of various diseases. In particular with regard to chronical and/or severe clinical conditions like multiple sclerosis, rheumatoid arthritis or cancer they are considered the future of treatment. Also economically biological drugs are on their way up: The global biopharmaceuticals market is anticipated to reach about 400 billion USD by 2025. Which strategic alignment will help best to fill a successful pipeline?
More info >>

White Papers

galenIQ - The smart excipient

BENEO GmbH

galenIQ combines a multitude of outstanding characteristics and is suitable for a wide range of pharmaceutical applications. galenIQ can be used as more than just a bulk excipient. It also serves as an anti-caking agent, anti-humectant agent, stabilizer or oral care and taste agent to mention just a few additional functions.
More info >>

 
Industry Events

BIO-Europe® 2019 - 25th Annual International Partnering Conference

11-13 November 2019, Hamburg, Germany

The 25th annual BIO-Europe® event is the largest biotechnology partnering conference held in Europe. Over 4,350 global decision makers from biotechnology, pharma and finance annually attend BIO-Europe to identify new business opportunities and develop strategic relationships. Business development executives and dealmakers consider BIO-Europe a must-attend event and an effective business strategy enabling them to meet and present to numerous potential partners. BIO-Europe features the industry’s most advanced web-based partnering system enabling delegates from all parts of the biotechnology value chain to quickly identify, engage and enter into strategic relationships that drive their business successfully forward. BIO-Europe's world-class workshops, panels and active exhibition along with thousands of prescheduled one-to-one meetings make this event an unrivaled forum for companies across the biotech value chain to meet and do business. Learn more.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement